A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

NCT00362466 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Insufficient Enrollment

Conditions

Leukemia

Interventions

DRUG: Dasatinib
DRUG: Imatinib

Sponsor

Bristol-Myers Squibb